Scott Gottlieb’s FDA Commissioner Confirmation Hearing: Remarkably Unremarkable image

Health Affairs Blog, April 7, 2017
Rachel E. Sachs (Academic Fellow Alumna)

Links

Read the full post

From the post:

On Wednesday morning, the United States Senate Committee on Health, Energy, Labor, and Pensions conducted the confirmation hearing for Dr. Scott Gottlieb, President Trump’s nominee to be the next Commissioner of the Food & Drug Administration (FDA). In a presidential administration whose confirmation hearings have sparked more than a few contentious moments, Dr. Gottlieb’s hearing was remarkable for how unremarkable it was. Senators from both parties asked questions on the full range of the FDA’s jurisdiction, and Dr. Gottlieb’s experience combined with his clear preparation for the hearing resulted in an uneventful, two-and-a-half hour hearing.

But to say that Dr. Gottlieb’s hearing was uneventful is not to say that it was uninteresting. In my view, Dr. Gottlieb was asked about four categories of issues that are worth considering for insight into how is he is likely to lead the agency. Further, he was not asked about a fifth issue that in my view is critically important for the next commissioner.

 

Read more here!

biotechnology fda health care finance health care reform health law policy pharmaceuticals rachel sachs regulation